KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Debt Repayments (2016 - 2017)

Historic Long-Term Debt Repayments for Regeneron Pharmaceuticals (REGN) over the last 9 years, with Q4 2017 value amounting to -$37.1 million.

  • Regeneron Pharmaceuticals' Long-Term Debt Repayments fell 28411.91% to -$37.1 million in Q4 2017 from the same period last year, while for Sep 2018 it was -$37.1 million, marking a year-over-year decrease of 14808.81%. This contributed to the annual value of $19.9 million for FY2017, which is 3932.93% down from last year.
  • Regeneron Pharmaceuticals' Long-Term Debt Repayments amounted to -$37.1 million in Q4 2017, which was down 28411.91% from $57.0 million recorded in Q1 2017.
  • In the past 5 years, Regeneron Pharmaceuticals' Long-Term Debt Repayments ranged from a high of $159.5 million in Q4 2014 and a low of -$37.1 million during Q4 2017
  • Over the past 5 years, Regeneron Pharmaceuticals' median Long-Term Debt Repayments value was $6.5 million (recorded in 2015), while the average stood at $27.4 million.
  • In the last 5 years, Regeneron Pharmaceuticals' Long-Term Debt Repayments crashed by 70614.62% in 2013 and then skyrocketed by 1753994.25% in 2014.
  • Over the past 5 years, Regeneron Pharmaceuticals' Long-Term Debt Repayments (Quarter) stood at -$3.6 million in 2013, then surged by 4471.44% to $159.5 million in 2014, then tumbled by 87.15% to $20.5 million in 2015, then fell by 1.67% to $20.2 million in 2016, then plummeted by 284.12% to -$37.1 million in 2017.
  • Its Long-Term Debt Repayments was -$37.1 million in Q4 2017, compared to $57.0 million in Q1 2017 and $20.2 million in Q4 2016.